CD133+ Autologous Cells After Myocardial Infarction

Institute of Hospitalization and Scientific Care (IRCCS)

Status and phase: Completed; Phase 2; Phase 1

Conditions: Acute Myocardial Infarction

Treatments: Procedure: cd133+cell intracoronary administration

Study type: Interventional

Funder types: Other

Identifiers

NCT00400959

CFT92002

Details and patient eligibility

About

TITLE Intracoronary injection of CD133+ autologous hematopoietic cells after myocardial infarction.

TRIAL DESIGN Pilot phase I/II parallel group study, with an untreated control group.

SPONSOR IRCCS Ospedale Maggiore Policlinico Milano INDICATION Acute myocardial infarction (AMI). TARGET POPULATION Patients (pts) with AMI treated with Primary Coronary Angioplasty (PTCA) with successful recanalization but unsuccessful reperfusion (myocardial blush (MB) grade 0 or 1 and less than 70% ST segment elevation resolution (STeR) (see Poli et al., Circulation, 2002).

OBJECTIVES Primary:

1. To evaluate the safety of intracoronary injection of CD133+ cells from autologous bone marrow (ABM) and mobilized peripheral blood (MPB) in the target population.

2. To evaluate the efficacy, of the selective injection of CD133+ cells from ABM and MPB in the culprit vessel of the target population, on regional and global contractile function and on perfusion and metabolism of the infarcted area, depending on cell dose and comparing to controls.

   Secondary:

3. To evaluate the disease-related morbility of the target population.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent;
• age: 18-65 years;
• large acute myocardial infarction (due to proximal occlusion of the left anterior descending or the right coronary artery) after successful primary PTCA carried out between the IV and the XXIV hour from the onset of AMI symptoms;
• signs of microvascular dysfunction in the infarcted area: absence of STeR and angiographic MB, graded according to the dye density score (see van't Hof et al., Circulation, 1998); life expectancy more than 6 months.

Exclusion criteria

• Pregnancy;
• indication to aorto-coronaric by-pass;
• neoplasia (previous or in progress);
• primary diseases of the BM;
• diabetes;
• immunosuppressive therapy;
• laboratory alterations of protein S, protein C, ATIII or Fibrinogen;
• severe co-morbidity.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)